Abstract
Abstract only
- Title
- Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study
- Creators
- Robert Allen Burger - University of PennsylvaniaDanielle Enserro - NRG OncologyKrishnansu Sujata Tewari - University of California, IrvineMark F. Brady - Roswell Park Cancer InstituteMichael A. Bookman - University of ArizonaGini F. Fleming - University of ChicagoHelen Q Huang - GOG Statistical and Data Center, Rochester, NYHoward D. Homesley - East Carolina UniversityJeffrey Fowler - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteMatthew Boente - Genentech, Inc., San Francisco, CALeslie M. Randall - University of California, IrvineJohn K. Chan - Palo Alto Medical FoundationJames Stuart Ferris - University Medical Center - Breckenridge Shivers Center, Austin, TXPhilip J. DiSaia - University of California, Irvine Medical CenterLarry J. Copeland - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteRobert S. Mannel - Oklahoma State University Oklahoma CityMichael J. Birrer - University of Alabama at BirminghamBradley J. Monk - University of Arizona
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.5517-5517
- Identifiers
- 991005968787502656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article